OHSU Drug Effectiveness Review Project Summary Report – Deflazacort oral tablet

Date of Review: July 2017
Generic Name: deflazacort

End Date of Literature Searcy: 05/22/2017
Brand Name (Manufacturer): Emflaza™ (PTC Therapeutics)
Dossier Received: Yes

Research Questions:
1. What is the comparative efficacy or effectiveness of deflazacort compared to currently available corticosteroids in improving clinical outcomes (including improved muscle strength and mobility, prevention of long-term cardiac and pulmonary complications, and increased survival) in patients with Duchenne Muscular Dystrophy (DMD)?
2. Is deflazacort safe for treatment of DMD and what is the relative safety compared to other corticosteroids?
3. Are there any subgroups (based on age, gender, ethnicity, comorbidities, disease duration or severity) that would particularly benefit or be harmed from treatment with deflazacort?

Conclusions:
- The report conducted by the Drug Effectiveness Review Project (DERP) evaluated deflazacort for the treatment of DMD based on 4 randomized controlled trials (RCT), 3 systematic reviews, and one guideline.
- Four RCTs of poor methodological quality showed insufficient evidence that demonstrated no difference in muscle strength and motor outcomes between deflazacort and prednisone for patients with DMD.
- Similarly, there is a lack of quality evidence evaluating comparative differences in adverse effects between deflazacort and prednisone. Evidence that deflazacort is associated with significantly less weight gain (mean difference [MD] 2.91 to 4.1 kg) but more cataracts than prednisone was of insufficient quality. Due to significant methodological limitations of these trials and lack of reported data, the true treatment effect is likely to be substantially different from the estimated treatment effect. Two of these RCTs were completed more than 20 years ago, and only one included patients in the United States. As a result, these data may not be applicable to patients under the Oregon Health Plan (OHP) today. There was no comparative evidence of deflazacort and prednisone beyond 2 years of follow-up.
- There is insufficient evidence to evaluate differences between deflazacort and other corticosteroids for DMD or other conditions.
- Overall, there is insufficient evidence to evaluate differences in adverse effects between deflazacort and other oral corticosteroids. Evidence is limited by small sample sizes, lack of reported methodology and outcomes, and inadequate data in a United States population of patients.

Recommendations:
- Implement prior authorization criteria that restricts use to patients with DMD and documented contraindication or serious intolerance to oral corticosteroids (Appendix 3).
Referring deflazacort to the Health Evidence Resource Commission (HERC) for funding placement as a drug with high cost and marginal benefit compared to currently available low-cost oral corticosteroids.

**Background:**
Duchenne muscular dystrophy (DMD) is a rare X-linked genetic disorder caused by the absence of a functional dystrophin protein. Duchenne’s is the most common type of muscular dystrophy occurring in approximately 1 in 7250 males between the ages of 5 to 24 years. Currently, in the Oregon Health Plan (OHP) population, approximately 70 fee-for-service patients and more than 300 patients enrolled in coordinated care organizations have a diagnosis of muscular dystrophy. Available claims data for OHP are unable to distinguish between patients with various types of muscular dystrophy. Based on the estimated prevalence of DMD, approximately 60 OHP patients with muscular dystrophy may be eligible for this medication. Patients with DMD experience progressive muscle deterioration leading to loss of ambulation and decreased muscle strength. Long-term complications include pulmonary problems, dilated cardiomyopathy, arrhythmias, and increased risk for thrombotic events. In many patients, these complications can lead to wheelchair dependence by age 12 and death before the age of 20. Only 25% of patients remain ambulatory by age 16. There is currently no curative treatment, and therapy focuses on improving symptoms, enhancing quality of life, and decreasing disease progression. Guidelines from the American Academy of Neurology recommend either deflazacort or prednisone as first-line treatment in children over 5 years of age to improve muscle and pulmonary function and reduce risk of scoliosis. Other non-pharmacological therapies which are often essential in disease management include physical therapy and use of support devices such as braces and wheelchairs. As the disease progresses, mechanical ventilation and spinal surgery may be used to improve pulmonary function and decrease pain from scoliosis and vertebral fractures.

Deflazacort is a corticosteroid which has been on the market in Europe and other countries for decades, but only recently achieved FDA approval in the United States. Deflazacort was approved through the FDA priority review process for the treatment of DMD in patients age 5 years and older based on the results of 2 randomized active-comparator trials including 196 and 18 patients each. The primary outcome evaluated change in muscle strength measured by a modified Medical Research Council scale. The Medical Research Council scale (MRC) ranges from 0 to 10 points, with higher scores indicating greater strength. A score of 10 indicates the muscle is able to contract against full resistance and 0 represents no movement observed. Scores are typically assessed and summarized for several muscle groups in several positions (sitting, prone, supine, and lying on the side). The minimum clinically important difference with this scale has not been established. Other studies evaluated change in muscle function using timed function tests such as the time required to walk a certain distance. Other methods to evaluate functional improvement included use of the Motor Function Index which evaluates a patient’s ability to climb four 17 cm stairs, stand from a sitting position, and walk 10 meters on flat ground. Each test is evaluated on a 1-3 scale indicating if individuals are able to complete the task without assistance (1 point), accomplish the task with assistance (2 points), or are not able to complete the task (3 points). Total scores range from 3 to 9 with larger scores indicating more severe disease. The validity of this scale and minimum clinically important change has not been determined.

Deflazacort has also been studied for treatment on multiple conditions including idiopathic thrombocytic purpura, essential mixed cryoglobulinemia, juvenile chronic arthritis, nephrotic syndrome, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, solid organ transplant rejection, and urolithiasis. Randomized controlled trials have examined the efficacy or safety of deflazacort compared to other corticosteroids. However, long-term population-based studies indicate that oral prednisone may be associated with greater incidence of weight gain, hirsutism and cushingoid appearance, while deflazacort may have greater risk of cataracts. The DERP review summarizes comparative evidence of deflazacort versus other corticosteroids for the treatment of DMD. Evidence for other potential off-label conditions will also be considered in this report.

**Author:** S. Servid  
**Date:** July 2017
See Appendix 1 for Highlights of Prescribing Information from the manufacturer, including Boxed Warnings and Risk Evaluation Mitigation Strategies (if applicable), indications, dosage and administration, formulations, contraindications, warnings and precautions, adverse reactions, drug interactions and use in specific populations.

Methods:
An April 2017 Drug Effectiveness Review Project (DERP) report compared deflazacort to prednisone for children with Duchenne Muscular Dystrophy was used to inform recommendations for this drug evaluation. The DERP report was supplemented with information from the manufacturer’s prescribing information and the FDA website. In addition, new evidence published since completion of the DERP report that evaluated use for FDA-approved indications or off-label conditions was identified. The Medline search strategy used for this review is available in Appendix 2, which includes dates, search terms and limits used. The Agency for Healthcare Research and Quality (AHRQ), the Cochrane Collaboration, National Institute for Health and Clinical Excellence (NICE), Department of Veterans Affairs, BMJ Clinical Evidence, and the Canadian Agency for Drugs and Technologies in Health (CADTH) resources were manually searched for high quality and relevant systematic reviews. Finally, the AHRQ National Guideline Clearinghouse (NGC) was searched for updated and recent evidence-based guidelines.

The DERP is part of the Pacific Northwest Evidence-based Practice Center at Oregon Health & Science University. The purpose of the DERP reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. DERP reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. OHSU does not recommend or endorse any guideline or recommendation developed by users of these reports. The original DERP report is available to Oregon Pharmacy and Therapeutics Committee members upon request. An executive summary report is publicly available in the agenda packet and on the DURM website.

Summary Findings: Duchenne Muscular Dystrophy
A total of 4 RCTs, 3 systematic reviews, and one guideline were identified in the DERP report. All trials included a similar population of patients (males at least age 5 with DMD), and all compared FDA-approved dosing of deflazacort 0.9 mg/kg/day to prednisone 0.75 mg/kg/day. Overall evidence from these trials was graded as poor quality due to significant methodological flaws and lack of reported data.

The primary study used for FDA approval included 196 males from the United States and Canada randomized to deflazacort 0.9 mg/kg/day, deflazacort 1.2 mg/kg/day, prednisone 0.75 mg/kg/day, or placebo. At 12 weeks, patients in the placebo group were re-randomized to a treatment arm. The trial was completed in 1995, and at this time the distinction between types of muscular dystrophy was not well defined. As a result, this trial included patients with either Duchenne or Becker muscular dystrophy limiting applicability to patients with DMD today. The primary outcome was change in muscle strength at 12 weeks measured using a modified MRC index score. Scores are based on several muscle strength assessments and evaluated on a 0 to 10 point rating scale with lower scores indicating more severe disease. Secondary outcomes included muscle strength at 1 year, motor function, pulmonary function, disease severity, adverse effects, weight gain and change in growth. Outcomes are summarized in Table 1. Actual MRC scores at baseline, 12 weeks and 1 year were not reported and numbers represent the change in MRC score from baseline. Overall, there was no significant difference in muscle strength between patients treated with either corticosteroid at 12 weeks or 1 year. Compared to placebo at 12 weeks, these differences in MRC were statistically significant for both groups, though the clinical significance of 0.25 to 0.38 points is questionable. There was no difference between deflazacort and prednisone in timed motor function tests between groups at 1 year. Timed motor function tests included time to stand from a supine position, climb 4 stairs, run or walk 30 feet, or propel a wheelchair 30 feet. This evidence had several important limitations which decrease confidence in these results including potential conflicts of interest and lack of information on randomization methods, allocation concealment, and baseline disease severity between groups.
Table 1. Mean change in MRC Score* from Baseline (95% CI).8

<table>
<thead>
<tr>
<th></th>
<th>12 weeks</th>
<th>1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>-0.1 (-0.23 to 0.03)</td>
<td>-</td>
</tr>
<tr>
<td>Deflazacort 0.9 mg/kg</td>
<td>0.15 (0.01 to 0.28)*</td>
<td>0.39 (0.25 to 0.54)</td>
</tr>
<tr>
<td>Deflazacort 1.2 mg/kg</td>
<td>0.26 (0.12 to 0.40)*</td>
<td>0.38 (0.23 to 0.54)</td>
</tr>
<tr>
<td>Prednisone 0.75 mg/kg</td>
<td>0.27 (0.13 to 0.41)*</td>
<td>0.23 (0.07 to 0.38)</td>
</tr>
</tbody>
</table>

*Statistically different from placebo.

*MRC score was evaluated on a 0 to 10 point scale.

A second trial of 100 German patients also evaluated the comparative efficacy and safety of prednisone and deflazacort.2 Overall, data from this study were rated as poor quality due to significant methodological flaws and lack of reported data. Preliminary results of this RCT including 67 patients were published in 1995 and final results including all 100 patients were available in an unpublished conference report in 2000.2 Of the 100 patients enrolled, 80% remained in the trial at 2 years.2 Overall, there was no difference in muscle function or strength between groups. However, numerical data for these outcomes were not reported, and results from this trial were limited by highly disparate attrition rates between groups without use of an intention-to-treat analysis.2

The third RCT was double-blinded and included 18 Italian patients followed for 2 years.2 Patients were randomized to prednisone or deflazacort and reportedly stratified by disease severity and age.2 However, methods used for randomization and allocation concealment were unclear.2 Outcomes reported at 1 and 2 years included muscle strength, motor outcomes (reported descriptively) and weight gain. No difference was observed in muscle strength or functional scores at 2 years.2 This study was significantly limited by the small sample size, lack of reported outcomes, and significant risk of bias.2

Another RCT evaluated 34 Iranian patients randomized to deflazacort or prednisone.2 The study was limited by poor reporting of methodological methods including methods of randomization, allocation concealment, blinding, and baseline characteristics for each group.2 In addition, a significant portion of patients were lost to follow up with high differential rates between groups (17.6% in deflazacort vs. 29.4% in prednisone group) increasing risk of bias.2 The efficacy outcomes evaluated included change in the motor function index (Table 2) up to 18 months. The motor function index evaluates functional status on a 7-point scale (range 3-9) with larger scores indicating more severe disease.5 At 12 months, patients treated with deflazacort had a statistically significant increase from baseline in the mean motor function index compared to prednisone, but differences failed to achieve statistical significance at 18 months.2,5

Table 2. Motor function index reported as mean score (95% CI) and mean difference (MD) from baseline.5

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>12 months</th>
<th>18 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deflazacort 0.9 mg/kg</td>
<td>4.93 (95% CI 4.4 to 5.5)</td>
<td>4.36 (95% CI 3.7 to 5.0); MD -0.57</td>
<td>4.64 (95% CI 3.8 to 5.5); MD -0.29</td>
</tr>
<tr>
<td>Prednisone 0.75 mg/kg</td>
<td>5.0 (95% CI 4.6 to 5.5)</td>
<td>5.25 (95% CI 4.4 to 6.1); MD 0.25</td>
<td>5.75 (95% CI 4.4 to 7.2); MD 0.75</td>
</tr>
<tr>
<td>Mean difference between groups</td>
<td>0.82; p=0.001</td>
<td>1.04; p=0.128</td>
<td></td>
</tr>
</tbody>
</table>

Three systematic reviews also evaluated comparative efficacy and safety between prednisone and deflazacort.2 Though the RCTs included in these reviews differed, they all reached similar conclusions. Evidence for motor outcomes was graded as insufficient to very low quality demonstrating no difference in efficacy between deflazacort and prednisone.2
One guideline from the American Academy of Neurology on use of corticosteroids for treatment of DMD was included in the DERP report. Evidence supporting recommendations in this guideline included one RCT and multiple observational studies that evaluated the comparative effectiveness of deflazacort and prednisone. The majority of observational evidence included cohort or case-control studies with a defined control group, masked outcome assessment, and description of potential confounding factors. Overall, evidence was graded as moderate quality indicating moderate assessment of benefit versus risk, low quality indicating small benefit relative to risk, or very low quality indicating there is insufficient evidence to evaluate risk versus benefit. Due to limitations in the evidence, many recommendations are graded as low quality. No specific recommendations are made for any particular agent. Evidence supporting use of prednisone to improve strength and pulmonary function was rated as moderate quality. There was low quality evidence to support use of deflazacort to improve strength and pulmonary function, delay loss of ambulation by 1.4 to 2.5 years, and increase survival at 5 or 15 years. Evidence regarding survival was primarily derived from 3 observational studies which demonstrated increased mortality in untreated patients (21-43%) compared to those treated with deflazacort (3-11%). Six observational studies evaluated outcomes of muscle strength and ambulation with deflazacort treatment and demonstrated improvements in motor outcomes using various measures. In 3 of these studies, the age at which patients lost ambulation was improved by 1.4 to 2.5 years in patients treated with deflazacort compared to no treatment. Two additional studies evaluating both prednisone and deflazacort demonstrated improvements in age at loss of ambulation for both medications. Evidence evaluating the need for scoliosis surgery, delaying the onset of cardiomyopathy, and improving timed motor function tests was evaluated as low quality for both prednisone and deflazacort. Similarly, there was low quality evidence that deflazacort and prednisone provide similar improvements in motor function, and low quality evidence that deflazacort has less weight gain but greater risk for cataracts than prednisone. Direct comparative evidence included 2 observational studies that demonstrated no difference in functional motor outcomes over 1 year and 5.49 years each. In these studies, weight gain was more common in the first year of treatment (mean weight increase of 21.3% with prednisone vs. 9% with deflazacort) corresponding to a mean weight increase at 1 year of 5.08 kg in patients treated with prednisone compared to 2.17 kg in patients treated with deflazacort (p<0.05). However, one study noted no difference in weight in older children (12-15 years). Cataracts occurred more often in patients treated with deflazacort compared to prednisone, though results were not statistically significant. There was insufficient evidence to compare differences between therapies for other outcomes including pulmonary and cardiac function.

Evidence evaluating adverse effects was also reported from these 4 RCTs. In the primary study used for FDA approval (n=196), patients randomized to deflazacort had less weight gain (5.05 kg) compared to prednisone (8.45 kg; MD 3.4 kg; p<0.0001) over the course of 1 year. However, incidence of cataracts was higher with deflazacort (6.6%) at 1 year compared to prednisone (4.4%; p-value not reported). Similar trends were noted between groups with evaluation of body mass index. Similarly in subsequent studies, patients treated with prednisone versus deflazacort reported higher incidence of weight gain leading to treatment discontinuation (data not reported) and more weight gain at 1 and 2 years (2.17 kg vs. 5.08 kg, p-value not reported and 4.6 kg vs. 8.7 kg; p<0.05, respectively). Another study reported that patients treated with prednisone had a greater mean percent increase in weight than patients treated with deflazacort at 12 months (21.7% vs. 13.0%; p=0.001) and 18 months (32% vs. 21.7%; p=0.046) corresponding to a mean 2.41 to 3.18 kg weight increase in patients treated with prednisone compared to deflazacort. One other study (n=100) also reported that more patients on deflazacort developed cataracts compared to patients treated with prednisone (36% vs. 3%, p-value not reported). However, evidence from these RCTs was limited by inadequate or unclear methods, lack of adequately reported data, and high and/or disparate attrition rates without use of intention-to-treat analyses. Systematic reviews evaluating adverse effects of deflazacort and prednisone also concluded that deflazacort was associated with less weight gain than prednisone though evidence was graded as very low quality indicating very little confidence in the estimated effect. Further studies are needed to evaluate comparative safety and adverse effects between deflazacort and other corticosteroids.
Because deflazacort is a corticosteroid, FDA labelling includes warnings and precautions for adverse effects which have been associated with corticosteroid use. Warnings are summarized in Appendix 1. Additional rare but serious adverse effects include effects on growth and development, myopathy, Kaposi’s sarcoma, thrombotic events, and anaphylaxis.\textsuperscript{10} Deflazacort suspension also includes benzyl alcohol preservative which has been associated with increased risk of serious and fatal reactions in infants and is not approved in children less than 5 years of age.\textsuperscript{10} Common adverse effects (occurring in >10% of patients compared to placebo at 12 weeks) included cushingoid appearance, weight gain, and increased appetite.\textsuperscript{10} Because clinical trials included a limited population of patients randomized to deflazacort and placebo (n=51 and 50), rates of adverse events may not be reflective of rates observed in clinical practice.\textsuperscript{10}

**Off-label Indications**

A high-quality systematic review published in 2012 examined the comparative efficacy and safety of deflazacort versus other corticosteroids for the treatment of nephrotic syndrome.\textsuperscript{11} The review included 3 single-center RCTs (n=91 patients total) in France, Denmark and Argentina.\textsuperscript{11} Patients were randomized to deflazacort or prednisone in 2 studies and to deflazacort or methylprednisolone in the third study.\textsuperscript{11} Two trials evaluated use in children and one evaluated adults with newly diagnosed nephrotic syndrome. Data for these trials were described descriptively as they did not consistently report similar outcomes and evaluated different populations. Two studies examine time to remission, with no apparent difference between patients randomized to deflazacort or another corticosteroid.\textsuperscript{11} In 1 study, the mean number of new relapses and the proportion of children who were relapse free at 1 year was improved with treatment of deflazacort compared to prednisone (MD 1.9; 0.9 vs. 2.8; p<0.002 and 60% vs. 10%; p=0.002, respectively).\textsuperscript{11} Another study reported no difference in the number of relapses after more than 4 years of follow-up.\textsuperscript{11} No significant difference was observed in mean growth velocity, fasting blood sugar, infection rate, or cushingoid symptoms when deflazacort was compared to other corticosteroids.\textsuperscript{11} One study did report a smaller mean decrease with deflazacort compared to prednisone in bone density (3.6 vs. 5.9 gHa; p<0.05) and bone mineral content (0.0050 vs. 0.0089 gHa/cm²/month; p<0.05) of the spine, while another study failed to achieve statistical significance between groups.\textsuperscript{11} Evidence was limited by lack of defined primary and secondary outcomes and small patient population.\textsuperscript{11} In addition, one trial failed to report adequate randomization methods, and in another, providers and outcome assessors were not blinded, increasing risk of bias.\textsuperscript{11}

**Randomized Controlled Trials:**

A total of 155 citations were manually reviewed from the initial literature search. The Medline search strategy used for this review is available in Appendix 2, which includes dates, search terms and limits used. After further review, 139 citations were excluded because of wrong study design (eg, observational), comparator (eg, no control or placebo-controlled), population (eg, healthy subjects), or outcome (eg, non-clinical). Several excluded trials examined effects on bone mineral density or content. However, bone mineral density can vary between instruments and trials did not report outcomes using standardized methods (i.e. T-score or Z-score) making interpretation of these outcomes difficult. The remaining 20 trials were critically evaluated for internal validity and risk of bias. Seven trials were excluded due to substantial flaws and lack of reported methods which significantly increase risk for selection bias (i.e. methods of randomization and allocation concealment, inclusion and exclusion criteria, and relevant baseline characteristics were not reported), and results should not be considered in the decision-making process. Results of the remaining trials which evaluate evidence for deflazacort in off-label conditions are summarized in the table below. Overall, evidence is limited by small population size, significant methodological flaws, and lack of reported outcomes which increases risk of bias. In addition, the majority of studies were completed outside the United States at a single medical center, and published more than 15 years ago limiting applicability to the OHP population today.
<table>
<thead>
<tr>
<th>Study/Loc.</th>
<th>Comparison</th>
<th>Population/Location</th>
<th>Primary Outcome</th>
<th>Results</th>
<th>Study Limitations and Potential Sources of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grosso S, et al. 2008.</td>
<td>1. Hydrocortisone daily and tapered at monthly intervals on the following schedule: 10 mg/kg, 5 mg/kg, 2.5 mg/kg, 1 mg/kg, and 1 mg/kg on alternate days, thereafter 2. Deflazacort 0.75 mg/kg</td>
<td>Children with drug-resistant epilepsy Italy</td>
<td>Proportion of patients with &gt;50% decreased seizure frequency at 6 months</td>
<td>1. 44% 2. 47% P=0.9</td>
<td>Patients and providers were not blinded and patients were allocated to groups on an alternate basis at hospitalization increasing risk of bias. Allocation concealment was not reported.</td>
</tr>
<tr>
<td>Elli A, et al. 1993.</td>
<td>1. Deflazacort 2. Methylprednisolone</td>
<td>Kidney transplant patients Italy</td>
<td>No primary outcome specified. Clinical outcomes included rejection episodes and weight gain at 1 year</td>
<td>Acute rejection episodes 1. 9 (36%) 2. 11 (44%) p-value NS Mean change in weight 1. 1.25 kg 2. 2.8 kg P&lt;0.05</td>
<td>Inclusion and exclusion criteria were not specified. Randomization and allocation concealment methods were unclear. Baseline weight was higher in patients treated with methylprednisolone (2.7kg). Open-label study increases risk of bias. Primary and secondary outcomes were not specified and multiple outcomes were examined without methods to control for multiplicity increasing risk of reporting bias.</td>
</tr>
<tr>
<td>Kim Y, et al. 1997.</td>
<td>1. Deflazacort 2. Prednisolone</td>
<td>Kidney transplant patients with pre- or post-transplant DM Korea</td>
<td>No primary outcome specified. Outcomes included change in body weight, insulin requirements, acute rejection, adverse effects</td>
<td>50% dose reduction of insulin or diabetic agents 1. 12 (30.8%) 2. 2 (5%) P=0.023 Weight 1. 1.74 kg weight loss 2. 0.58 kg weight loss</td>
<td>Randomization and allocation concealment, methods were unclear. Primary and secondary outcomes were not specified and multiple outcomes were examined without methods to control for multiplicity increasing risk of bias.</td>
</tr>
<tr>
<td>Ferraris JR, et al. 2007.</td>
<td>1. Deflazacort 0.3 mg/kg/day 2. Methylprednisolone 0.2 mg/kg/day</td>
<td>Children following kidney transplantation (mean time since transplantation was 2.1 years) Argentina</td>
<td>No primary outcome specified. Outcomes included rates of adverse effects compared to baseline (growth, body weight, BMD, and effects on</td>
<td>No specified primary outcome. Multiple outcomes described descriptively. BMI was not significantly different between groups. More patients treated with deflazacort had an LDL&lt;100 mg/dL (p&lt;0.001) and normal</td>
<td>Randomization and allocation concealment methods were unclear. Patients and providers were not blinded increasing risk of bias. Primary and secondary outcomes were not pre-specified and were evaluated post-hoc. Adverse effects were evaluated using multiple analyses increasing risk of reporting bias. Multiple outcomes were described descriptively. Use of concomitant lipid or glucose-lowering therapies was not</td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
<td>Design</td>
<td>N</td>
<td>Duration</td>
<td>Comparator 1</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------</td>
<td>----------</td>
<td>----</td>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td>Saviola GL, et al.</td>
<td>2007</td>
<td>Single-center, OL, cross-over, RCT</td>
<td>21</td>
<td>1 yr</td>
<td>Deflazacort 7.5 mg/day</td>
</tr>
<tr>
<td>Messina O, et al.</td>
<td>1992</td>
<td>DB, RCT</td>
<td>16</td>
<td>1 yr</td>
<td>Deflazacort 12 mg/day</td>
</tr>
<tr>
<td>Loftus J, et al.</td>
<td>1991</td>
<td>DB, RCT</td>
<td>34</td>
<td>1 yr</td>
<td>Deflazacort (mean dose 9.07 mg/day)</td>
</tr>
<tr>
<td>Gray R, et al.</td>
<td>1991</td>
<td>Blinded, RCT</td>
<td>26</td>
<td>N/A</td>
<td>Deflazacort</td>
</tr>
<tr>
<td>Duration: 3 months</td>
<td>Duration: 12 weeks</td>
<td>Polymyalgia rheumatica</td>
<td>Mean pain scores</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Di Munno O, et al. 1995.&lt;sup&gt;20&lt;/sup&gt;</td>
<td>Cross-over, DB, RCT&lt;br&gt;N=31</td>
<td>No primary outcome specified. Clinical outcomes included pain scores (evaluated by visual analogue scale) and morning stiffness</td>
<td>1. -4.5 2. -4.6 3. -6.3 4. -6.0 p-values NS between all</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Di Munno O, et al. 1995.&lt;sup&gt;20&lt;/sup&gt;</td>
<td>Duration: 12 weeks</td>
<td>After 2 weeks, dose was titrated based on clinical response. At 6 weeks patients were allocated to the alternate dosing regimen (daily vs. alternate day).</td>
<td>Mean change in morning stiffness from baseline (minutes) 1. -83 2. -84 3. -132 4. -116</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eberhardt R, et al. 1994.&lt;sup&gt;21&lt;/sup&gt;</td>
<td>DB, MC, RCT&lt;br&gt;N=76</td>
<td>Patients with RA Germany</td>
<td>Ritchie index at 12 months (SD) 1. 12.8 (7.46) 2. 9.8 (7.6) P=0.4954</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eberhardt R, et al. 1994.&lt;sup&gt;21&lt;/sup&gt;</td>
<td>Duration: 12 months</td>
<td>1. Deflazacort 24 mg daily 2. Deflazacort 48 mg on alternate days 3. Methylprednisolone 16 mg daily 4. Methylprednisolone 32 mg on alternate days</td>
<td>Randomization, allocation concealment methods were unclear. Blinding achieved with use of identical packaging though tablets had different appearances. 7 patients (23%) were excluded from the analysis. Primary and secondary outcomes were not specified and multiple outcomes were examined without methods to control for multiplicity increasing risk of reporting bias.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lund B, et al. 1987.&lt;sup&gt;22&lt;/sup&gt;</td>
<td>DB, cross-over, RCT&lt;br&gt;N=30</td>
<td>Patients with polymyalgia rheumatic Denemark</td>
<td>Disease activity, pain and tenderness evaluated using a visual analog scale</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lund B, et al. 1987.&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Disease duration was longer for patients treated with deflazacort (5.6 vs. 3.5 years). Dose and duration of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rizzato G, et al. 1997.&lt;sup&gt;23&lt;/sup&gt;</td>
<td>OL, RCT</td>
<td>Patients with chronic pulmonary sarcoidosis</td>
<td>Results described descriptively. No difference was observed in general disease activity, pain or tenderness.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rizzato G, et al. 1997.&lt;sup&gt;23&lt;/sup&gt;</td>
<td></td>
<td>1. Deflazacort 2. Prednisone</td>
<td>Randomization methods were unclear and baseline disease severity for each group was not reported. Multiple analyses performed without methods to control for multiplicity. Study not powered to determine differences in outcomes.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Di Munno O, et al. 1995.<sup>20</sup>**

Diagnosis: Polymyalgia rheumatica

**Cross-over, DB, RCT**

**N=31**

**Duration: 12 weeks**

1. Deflazacort 24 mg daily
2. Deflazacort 48 mg on alternate days
3. Methylprednisolone 16 mg daily
4. Methylprednisolone 32 mg on alternate days

After 2 weeks, dose was titrated based on clinical response. At 6 weeks patients were allocated to the alternate dosing regimen (daily vs. alternate day).

**Eberhardt R, et al. 1994.<sup>21</sup>**

**DB, MC, RCT**

**N=76**

**Duration: 12 months**

1. Deflazacort
2. Prednisone

Mean daily dose was 8.5 mg deflazacort and 7.3 mg prednisone.

**Eberhardt R, et al. 1994.<sup>21</sup>**

**DB, MC, RCT**

**N=76**

**Duration: 12 months**

1. Deflazacort
2. Prednisone

Mean daily dose was 8.5 mg deflazacort and 7.3 mg prednisone.

**Lund B, et al. 1987.<sup>22</sup>**

**DB, cross-over, RCT**

**N=30**

1. Deflazacort
2. Prednisone

Dosing administered in a ratio of 1.2-1.8 mg deflazacort to 1 mg prednisone for 2 week periods
N=72
Mean duration:
42 months

Mean starting dose was 22 mg for each group and tapered based on clinical requirements

included fracture events

treatment were not equivalent. Open-label trial further increases risk of bias. Primary and secondary outcomes were not specified and multiple outcomes were examined without methods to control for multiplicity increasing risk of bias. Bone toxicity analysis only reported in 58 patients (80%).

OL, RCT
N=27
Duration: 24 weeks

1. Deflazacort 1.4 mg/kg/day
2. Prednisone 1 mg/kg/day

Treatment was tapered upon complete response to treatment (platelet count >150) or completion of 4 weeks of treatment

Autoimmune thrombocytopenic purpura

No primary outcome specified. Clinical efficacy outcomes included complete response (platelet count >150) and no response (platelet count <50) after 24 weeks

Complete response
1. 2/11 (18%)
2. 2/12 (17%)

No treatment response
1. 4/11 (36%)
2. 4/12 (33%)
p-values NS

Randomization and allocation concealment methods were unclear. Open label design increases risk of bias. Primary and secondary outcomes were not specified and multiple outcomes were examined without methods to control for multiplicity increasing risk of bias. Four patients (14.8%) were excluded increasing risk of attrition bias. Study was not powered to determine differences in outcomes.

Abbreviations: ACR50 = 50% improvement in the American College of Rheumatology criteria; BMD = bone mineral density; BMI = bod mass index; DMD = Duchenne Muscular Dystrophy; DXA = dual x-ray absorptiometry; ESRD = end-stage renal disease; MC = multicenter; MD = mean difference; NR = not reported; NS = not significant; OL = open-label; RA = rheumatoid arthritis; RCT = randomized clinical trial; SD = standard deviation; yrs = years.

Table 1. Pharmacology and Pharmacokinetic Properties.1,10

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Corticosteroid prodrug which has anti-inflammatory and immunosuppressant properties. The exact mechanism in patients with</td>
</tr>
<tr>
<td></td>
<td>Duchenne muscular dystrophy is unclear.</td>
</tr>
<tr>
<td>Oral Bioavailability</td>
<td>Not reported; area under the curve is unchanged upon administration with food</td>
</tr>
</tbody>
</table>
| Distribution and Protein Binding | Protein binding = 40%
Exact volume of distribution is unknown                                     |
| Elimination                | 68% excreted unchanged in urine
18% metabolized                                                               |
| Half-Life                  | Half-life of approximately 1.17 to 2.4 hours. Elimination is almost complete by 24 hours after a single dose.                |
| Metabolism                 | Converted to the active metabolite, 21-des-deflazacort by esterase
Metabolized via CYP3A4 and p-glycoprotein                                   |
References:

1. Deflazacort Medical Review. US Food and Drug Administration Center for Drug Evaluation and Research. [https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684,208685Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684,208685Orig1s000TOC.cfm).


3. Deflazacort Summary Review. US Food and Drug Administration Center for Drug Evaluation and Research. [https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684,208685Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208684,208685Orig1s000TOC.cfm).


HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use EMFLAZA™ safely and effectively. See full prescribing information for EMFLAZA.

EMFLAZA (deflazacort) tablets, for oral use
EMFLAZA (deflazacort) oral suspension
Initial U.S. Approval: 2017

-----INDICATIONS AND USAGE-----
EMFLAZA is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older (1)

-----DOSEAGE AND ADMINISTRATION-----
• The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally (2.1)
• Discontinue gradually when administered for more than a few days (2.2)

-----DOSEAGE FORMS AND STRENGTHS-----
• Tablets: 6 mg, 18 mg, 30 mg, and 36 mg (3)
• Oral Suspension: 22.75 mg/mL (3)

-----CONTRAINDICATIONS-----
Hypersensitivity to deflazacort or any of the inactive ingredients in EMFLAZA (4)

-----WARNINGS AND PRECAUTIONS-----
• Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia can occur; Monitor patients for these conditions with chronic use of EMFLAZA (2.2, 5.1)
• Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal; Signs and symptoms of infection may be masked (5.2)
• Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure and sodium, and for decreased potassium levels (5.3)
• Gastrointestinal Perforation: Increased risk in patients with certain GI disorders; Signs and symptoms may be masked (5.4)
• Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis (5.5)
• Effects on Bones: Monitor for decreases in bone mineral density with chronic use of EMFLAZA (5.6)
• Ophthalmic Effects: May include cataracts, infections, and glaucoma; Monitor intraocular pressure if EMFLAZA is continued for more than 6 weeks (5.7)
• Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids (5.8)
• Serious Skin Rashes: Discontinue at the first sign of rash, unless the rash is clearly not drug related (5.9)

-----ADVERSE REACTIONS-----
The most common adverse reactions (≥ 10% for EMFLAZA and greater than placebo) are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis (6.1)

-----DRUG INTERACTIONS-----
• Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of EMFLAZA (7.1)
• Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy (7.1)

To report SUSPECTED ADVERSE REACTIONS, contact Marathon Pharmaceuticals, LLC at 1-866-562-4620 or DrugSafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 02/2017
Appendix 2: Literature search

Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present

1. deflazacort.mp. 527
2. limit 1 to (english language and humans) 377
3. limit 2 to (clinical trial, all or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative study or controlled clinical trial or meta analysis or multicenter study or practice guideline or pragmatic clinical trial or randomized controlled trial or systematic reviews) 155

Appendix 3. Proposed Prior Authorization Criteria

Drugs for Duchenne Muscular Dystrophy

Goal(s):
- Encourage use of corticosteroids which have demonstrated long-term efficacy
- Restrict use of eteplirsen and deflazacort to patients with Duchenne Muscular Dystrophy and limit use of deflazacort to patients with contraindications or serious intolerance to other oral corticosteroids

Length of Authorization:
- 6 months

Requires PA:
- Eteplirsen
- Deflazacort

Covered Alternatives:
- Current PMPDP preferred drug list per OAR 410-121-0030 at www.orpdl.org
- Searchable site for Oregon FFS Drug Class listed at www.orpdl.org/drugs/

<table>
<thead>
<tr>
<th>Approval Criteria</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. What diagnosis is being treated?</td>
<td>Record ICD10 code.</td>
</tr>
</tbody>
</table>
## Approval Criteria

<table>
<thead>
<tr>
<th></th>
<th>Is the request for treatment of Duchenne Muscular Dystrophy?</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2.</td>
<td>Yes: Go to #3</td>
<td>No: Pass to RPh. Deny; medical appropriateness.</td>
<td>Note: Eteplirsen and deflazacort are not indicated for other forms of muscular dystrophy or other diagnoses.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Is the request for continuation of eteplirsen treatment?</td>
<td>Yes: Go to Renewal Criteria</td>
<td>No: Go to #7</td>
</tr>
<tr>
<td>4.</td>
<td>Is the patient ≥ 5 years of age?</td>
<td>Yes: Go to #5</td>
<td>No: Pass to RPh. Deny; medical appropriateness.</td>
</tr>
<tr>
<td>5.</td>
<td>Is the request for deflazacort?</td>
<td>Yes: Go to #6</td>
<td>No: Go to #7</td>
</tr>
<tr>
<td>6.</td>
<td>Does the patient have a documented contraindication or intolerance to oral prednisone that is not expected to crossover to deflazacort or other corticosteroids?</td>
<td>Yes: Approve for up to 6 months. Document contraindication or intolerance reaction.</td>
<td>No: Pass to RPh. Deny; medical appropriateness. Recommend trial of another oral corticosteroid.</td>
</tr>
</tbody>
</table>
| 7. | Does the patient have a diagnosis of Duchenne Muscular Dystrophy with one of the following genetic mutations amenable to exon 51 skipping:  
  - Deletion of exons 45 to 50  
  - Deletion of exons 48 to 50  
  - Deletion of exons 49 and 50  
  - Deletion of exon 50 OR  
  - Deletion of exon 52? | Yes: Go to #8 Document genetic testing. | No: Pass to RPh, Deny; medical appropriateness. |
| 8. | Has the patient been on a stable dose of corticosteroid for at least 6 months? | Yes: Go to #9 | No: Pass to RPh. Deny; medical appropriateness. |
| Approval Criteria |
|-------------------|-------------------------------------------------|-------------------------------------------------|
| 9. Is the patient ambulatory with a 6-minute walk distance greater than 200 meters? | **Yes:** Document baseline 6-minute walk distance and approve for up to 6 months | **No:** Pass to RPh. Deny; medical appropriateness. |

| Renewal Criteria |
|-------------------|-------------------------------------------------|-------------------------------------------------|
| 1. Does the patient remain ambulatory? | **Yes:** Go to #2 | **No:** Pass to RPh, Deny; medical appropriateness. |
| 2. Has the patient maintained baseline functional level as evaluated by the following criteria: | **Yes:** Approve for up to 6 months Document functional status. | **No:** Pass to RPh, Deny; medical appropriateness. |
| ● 6-minute walking distance greater than baseline OR | | |
| ● 6-minute walking distance which has not declined by more than 30 meters or 10% of baseline, whichever is less? | | |